US (TX): Texas Original Compassionate Cultivation partners up with Vertosa

Texas Original Compassionate Cultivation (TOCC), Texas’ leading medical cannabis provider, today announced it has partnered with Vertosa, a science-first cannabis company that creates the most effective and reliable active ingredients for infused products. TOCC’s proven medical cannabis products will be the first and only in Texas to feature Vertosa’s solutions.

TOCC will use Vertosa’s nanoemulsion technology to enhance the patient experience through quicker onsets, product predictability and dosage consistency. TOCC’s new line of gummies will be its first physician-approved product to exclusively incorporate Vertosa’s nanoemulsion solutions. Available to TOCC patients on Sept. 1, 2021, the gummies will leverage Vertosa’s state-of-the-art, water-dispersible solutions to increase the gummies’ bioavailability, ultimately enhancing the benefits of medical cannabis for various conditions included in Texas’ Compassionate Use Program.

“As the medical cannabis leader in Texas, we’re always looking for ways to create and improve products on behalf of our patients,” said Morris Denton, CEO of TOCC. “The needs of our patients come first. We’ve heard time and again the importance of quality and consistency in our products. Vertosa’s fast-acting, consistent and safe solutions are the best in the cannabis industry, and we’re excited to bring their nanoemulsion technology and solutions to our patients in Texas.”

Vertosa’s industry-leading, high-quality emulsions are backed by science to better deliver active cannabis ingredients to consumers. The company collaborates with brands across the country to incorporate its emulsions into products such as cannabis-infused beverages, gummies and other form factors.

“We’re thrilled to collaborate with Texas’ leading medical cannabis provider and bring the unique advantages of our emulsion systems, like bioavailability and homogeneity, to the state’s market,” said Benjamin Larson, CEO of Vertosa. “Our emulsion technology will enable TOCC to customize its products and offer patients greater control in dosing and quicker onset upon administration with the highest quality ingredients.”